One of the phase I trials is studying the side effects and optimal dose of autologous DC‐adenovirus CCL21 vaccine combined with intravenous pembrolizumab and seeing how well they work in treating patients with stage IV nonsmall cell lung cancer (NCT03546361). Here, CCL21 is linked to lung cancer.